An urgent recall of a common antidepressant due to the presence of the wrong medication in the packaging, posing a direct patient safety risk for psychiatrists prescribing this drug.
The FDA has approved lumateperone (Caplyta) for the prevention of schizophrenia relapse, expanding its indication beyond acute treatment of schizophrenia and bipolar depression.
A common antidepressant is recalled in the UK because packaging errors resulted in packs containing the wrong medication, posing a direct risk to patient safety and treatment efficacy.
Ketamine therapy is being utilized as a treatment option for Israeli combat veterans with PTSD, highlighting its clinical application in this specific population.
A specific batch of sertraline has been recalled because the packaging contained a different antidepressant, posing a direct risk of medication error for patients.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Mar 25 – Apr 28)
- Utilize lumateperone (Caplyta) for relapse prevention in schizophrenia, leveraging its favorable metabolic and prolactin profile for long-term maintenance.
- Exercise extreme caution with sertraline prescriptions by verifying lot numbers and packaging integrity to avoid medication errors from recalled batches containing incorrect antidepressants.
- Maintain milnacipran for maternal stability in severe PTSD and psychotic depression during pregnancy, as switching to sertraline and quetiapine has been associated with rapid symptom relapse.
- Monitor for venous thromboembolism immediately upon initiating antipsychotic polypharmacy, as pulmonary embolism can occur within hours even in patients without traditional risk factors.
- Proactively monitor metabolic parameters and consider avoiding olanzapine or combined antipsychotic regimens to mitigate the high risk of obesity in schizophrenia.
- Assure patients that concurrent use of SSRIs or SNRIs does not significantly diminish the clinical response to ketamine or esketamine for treatment-resistant depression.
- Consider psilocybin as a pharmacologic option for smoking cessation, given evidence of superior efficacy compared to nicotine patches.
- Advocate for integrated multimodal care combining medication for opioid use disorder (MOUD) with psychotherapy, as this combination yields significantly higher remission rates than either modality alone.
- Monitor for delayed serotonin toxicity in patients with mixed overdoses involving diphenhydramine and dextromethorphan, as the toxidrome may evolve over time.
- Recognize that childhood ADHD medication may offer a protective effect against the future development of psychosis, supporting its use in high-risk populations.
Policy & Regulation 1
A precautionary recall of an antidepressant medication has been issued by the UK regulatory authority due to a manufacturing error, requiring prescribers to verify stock batches and consult official guidance for patient management.
Diagnosis & Treatment 4
A narrative review highlights elevated risks of cerebral amyloid angiopathy and immune-mediated adverse events for anti-amyloid monoclonal antibodies in Down syndrome, suggesting current exclusion from treatment guidelines is biologically justified pending further research.
This article critiques the comparative efficacy of psychedelic therapy versus antidepressants by highlighting the confounding influence of the placebo effect in unblinded trials.
This case report highlights the critical importance of maintaining milnacipran for maternal stability in severe PTSD and psychotic depression during pregnancy, as switching to sertraline and quetiapine resulted in rapid symptom relapse, while the infant showed no adverse developmental outcomes at 3-year follow-up.
A survey of individuals at clinical high risk for psychosis indicates high acceptability and willingness to use cannabidiol (CBD) as a treatment, with most preferring tablet or capsule formulations.
Clinical Pearl 5
This case report highlights the risk of delayed serotonin toxicity in mixed overdoses of diphenhydramine and dextromethorphan, emphasizing the need to monitor for evolving toxidromes in intentional ingestions.
A national multi-organization analysis demonstrates that combining MOUD (buprenorphine or methadone) with psychotherapy yields significantly higher remission rates for opioid use disorder than either modality alone, supporting integrated multimodal care.
Concurrent use of SSRIs, SNRIs, or other antidepressants does not significantly alter the clinical response or remission rates in patients receiving ketamine or esketamine for treatment-resistant depression.
A clinical trial comparing SSRIs to acupuncture for anxiety and depression, providing evidence on the relative efficacy of pharmacotherapy versus a non-pharmacologic intervention.
A clinical trial comparing SSRIs to acupuncture for anxiety and depression, providing evidence on the efficacy of a standard psychiatric pharmacotherapy against an alternative intervention.
Drug Development 1
Bristol-Myers Squibb's novel schizophrenia treatment has encountered early setbacks, signaling potential challenges for this new therapeutic approach in the treatment of schizophrenia.
Digital Health 1
A pilot study suggests that a culturally adapted digital CBT program can be safely used as an adjunct to pharmacotherapy to enhance reductions in pathological worry for patients with generalized anxiety disorder.
Substance Use 1
A single dose of psilocybin demonstrates superior efficacy compared to nicotine patches for smoking cessation, highlighting a novel pharmacologic approach to substance use disorder treatment.
Journal Article 1
This meta-analysis quantifies the 33% obesity incidence in schizophrenia and identifies olanzapine and combined antipsychotic regimens as major modifiable risk factors, supporting proactive metabolic monitoring and drug selection.
Pharmacogenomics 1
A postmortem study suggests that polygenic risk scores for ADHD and ASD may influence antipsychotic responsiveness in schizophrenia, highlighting potential pharmacogenomic implications for treatment outcomes.